Lipid-Lowering Agents: Targets Beyond PCSK9

Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease

Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487

Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel

Ference, B. A., Ginsberg, H. N., Graham, I., Ray, K. K., Packard, C. J., Bruckert, E., Hegele, R. A., Krauss, R. M., Raal, F. J., Schunkert, H., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx144 · Cited by 3,962

2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults

Stone, N. J., Robinson, J. G., Lichtenstein, A. H., Bairey Merz, C. N., Blum, C. B., Eckel, R. H., Goldberg, A. C., Gordon, D., Levy, D., Lloyd-Jones, D. M., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.11.002 · Cited by 3,845

Mendelian Randomization

Emdin, C. A., Khera, A. V., & Kathiresan, S. (2017) · JAMA · doi:10.1001/jama.2017.17219 · Cited by 3,637

Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia

Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317

Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease

Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181

Effects of torcetrapib in patients at high risk for coronary events

Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139

Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy

The AIM-HIGH Investigators (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107579 · Cited by 2,911

Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society

Nordestgaard, B. G., Chapman, M. J., Humphries, S. E., Ginsberg, H. N., Masana, L., Descamps, O. S., Wiklund, O., Hegele, R. A., Raal, F. J., Defesche, J. C., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht273 · Cited by 2,761

2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol

Grundy, S. M., Stone, N. J., Bailey, A. L., Beam, C., Birtcher, K. K., Blumenthal, R. S., Braun, L. T., de Ferranti, S., Faiella-Tommasino, J., Forman, D. E., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.11.003 · Cited by 2,691

The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial

Baigent, C., Landray, M. J., Reith, C., Emberson, J., Wheeler, D. C., Tomson, C., Wanner, C., Krane, V., Cass, A., Craig, J., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60739-3 · Cited by 2,479

Effects of dalcetrapib in patients with a recent acute coronary syndrome

Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022 · cited 1×

Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism

Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786

Lipoprotein(a) Concentration and the Risk of Coronary Heart Disease, Stroke, and Nonvascular Mortality

(2009) · JAMA · doi:10.1001/jama.2009.1063 · Cited by 1,753

Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease

Manson, J. E., Cook, N. R., Lee, I.-M. M., Christen, W., Bassuk, S. S., Mora, S., Luttmann‐Gibson, H., Gordon, D., Copeland, T., D’Agostino, D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809944 · Cited by 1,684

Genetic Variants Associated with Lp(a) Lipoprotein Level and Coronary Disease

Clarke, R., Peden, J. F., Hopewell, J. C., Kyriakou, T., Goel, A., Heath, S. C., Parish, S., Barlera, S., Franzosi, M. G., Rust, S., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902604 · Cited by 1,671

Effects of extended-release niacin with laropiprant in high-risk patients

The HPS2-THRIVE Collaborative Group (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1300955 · Cited by 1,668

Newly identified loci that influence lipid concentrations and risk of coronary artery disease

Willer, C. J., Sanna, S., Jackson, A. U., Scuteri, A., Bonnycastle, L. L., Clarke, R., Heath, S. C., Timpson, N. J., Najjar, S. S., Stringham, H. M., et al. (2008) · Nature Genetics · doi:10.1038/ng.76 · Cited by 1,585

Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174 000 participants in 27 randomised trials

(2015) · The Lancet · doi:10.1016/s0140-6736(14)61368-4 · Cited by 1,536

A Century of Cholesterol and Coronaries: From Plaques to Genes to Statins

Goldstein, J. L., & Brown, M. S. (2015) · Cell · doi:10.1016/j.cell.2015.01.036 · Cited by 1,233

A Test in Context: Lipoprotein(a)

Tsimikas, S. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.042 · Cited by 1,137

Loss-of-Function Mutations in APOC3, Triglycerides, and Coronary Disease

The TG and HDL Working Group of the Exome Sequencing Project, N. H. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1307095 · Cited by 1,071

Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society

Cuchel, M., Bruckert, E., Ginsberg, H. N., Raal, F. J., Santos, R. D., Hegele, R. A., Kuivenhoven, J. A., Nordestgaard, B. G., Descamps, O. S., Steinhagen-Thiessen, E., et al. (2014) · European Heart Journal · doi:10.1093/eurheartj/ehu274 · Cited by 1,057

Effects of anacetrapib in patients with atherosclerotic vascular disease

The HPS3/TIMI55–REVEAL Collaborative Group (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706444 · Cited by 1,047

Inclisiran in Patients at High Cardiovascular Risk with Elevated LDL Cholesterol

Ray, K. K., Landmesser, U., Leiter, L. A., Kallend, D., Dufour, R., Karakas, M., Hall, T., Troquay, R. P. T., Turner, T., Visseren, F. L. J., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615758 · Cited by 992

Diagnostic Yield and Clinical Utility of Sequencing Familial Hypercholesterolemia Genes in Patients With Severe Hypercholesterolemia

Khera, A. V., Won, H.-H., Peloso, G. M., Lawson, K. S., Bartz, T. M., Deng, X., van Leeuwen, E. M., Natarajan, P., Emdin, C. A., Bick, A. G., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.03.520 · Cited by 942

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

Raal, F. J., Santos, R. D., Blom, D. J., Marais, A. D., Charng, M., Cromwell, W. C., Lachmann, R., Gaudet, D., Tan, J. L., Chasan-Taber, S., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60284-x · Cited by 934

Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis

Jun, M., Foote, C., Lv, J., Neal, B., Patel, A., Nicholls, S. J., Grobbee, D. E., Cass, A., Chalmers, J., & Perkovic, V. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60656-3 · Cited by 927

Loss-of-Function Mutations in APOC3 and Risk of Ischemic Vascular Disease

Jørgensen, A. B., Frikke-Schmidt, R., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1308027 · Cited by 919

Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease

Dewey, F. E., Gusarova, V., Dunbar, R. L., O’Dushlaine, C., Schurmann, C., Gottesman, O., McCarthy, S., Van Hout, C. V., Bruse, S., Dansky, H. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612790 · Cited by 885

Increased High-Density Lipoprotein Levels Caused by a Common Cholesteryl-Ester Transfer Protein Gene Mutation

Inazu, A., Brown, M. L., Hesler, C. B., Agellon, L. B., Koizumi, J., Takata, K., Maruhama, Y., Mabuchi, H., & Tall, A. R. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011013231803 · Cited by 862

RNA-Targeted Therapeutics

Crooke, S. T., Witztum, J. L., Bennett, C. F., & Baker, B. F. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.004 · Cited by 841

Evacetrapib and cardiovascular outcomes in high-risk vascular disease

Lincoff, A. M., Nicholls, S. J., Riesmeyer, J. S., Barter, P. J., Brewer, H. B., Fox, K. A. A., Gibson, C. M., Granger, C., Menon, V., Montalescot, G., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609581 · Cited by 801

Exome Sequencing, ANGPTL3 Mutations, and Familial Combined Hypolipidemia

Musunuru, K., Pirruccello, J. P., Do, R., Peloso, G. M., Guiducci, C., Sougnez, C., Garimella, K. V., Fisher, S., Abreu, J., Barry, A. J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1002926 · Cited by 754

Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials

Viney, N. J., van Capelleveen, J. C., Geary, R. S., Xia, S., Tami, J. A., Yu, R. Z., Marcovina, S. M., Hughes, S. G., Graham, M. J., Crooke, R. M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31009-1 · Cited by 754 · cited 2×

Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study

Cuchel, M., Meagher, E. A., du Toit Theron, H., Blom, D. J., Marais, A. D., Hegele, R. A., Averna, M. R., Sirtori, C. R., Shah, P. K., Gaudet, D., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61731-0 · Cited by 744

Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies

Madsen, C. M., Varbo, A., & Nordestgaard, B. G. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx163 · Cited by 715

Validating therapeutic targets through human genetics

Plenge, R. M., Scolnick, E. M., & Altshuler, D. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4051 · Cited by 712

Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans

van der Valk, F. M., Bekkering, S., Kroon, J., Yeang, C., den Bossche, J. V., van Buul, J. D., Ravandi, A., Nederveen, A. J., Verberne, H. J., Scipione, C. A., et al. (2016) · Circulation · doi:10.1161/circulationaha.116.020838 · Cited by 706

Effects of n−3 Fatty Acid Supplements in Diabetes Mellitus

The ASCEND Study Collaborative Group (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804989 · Cited by 698

A Null Mutation in Human APOC3 Confers a Favorable Plasma Lipid Profile and Apparent Cardioprotection

Pollin, T. I., Damcott, C. M., Shen, H., Ott, S. H., Shelton, J., Horenstein, R. B., Post, W., McLenithan, J. C., Bielak, L. F., Peyser, P. A., et al. (2008) · Science · doi:10.1126/science.1161524 · Cited by 688

HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials

Swerdlow, D. I., Preiss, D., Kuchenbaecker, K. B., Holmes, M. V., Engmann, J. E. L., Shah, T., Sofat, R., Stender, S., Johnson, P. C. D., Scott, R. A., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61183-1 · Cited by 680

Structure, function, and genetics of lipoprotein (a)

Schmidt, K., Noureen, A., Kronenberg, F., & Utermann, G. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r067314 · Cited by 671

The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management

Hegele, R. A., Ginsberg, H. N., Chapman, M. J., Nordestgaard, B. G., Kuivenhoven, J. A., Averna, M., Borén, J., Bruckert, E., Catapano, A. L., Descamps, O. S., et al. (2014) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70191-8 · Cited by 635

Increased coronary heart disease in Japanese-American men with mutation in the cholesteryl ester transfer protein gene despite increased HDL levels.

Zhong, S., Sharp, D. S., Grove, J., Bruce, C., Yano, K., Curb, J. D., & Tall, A. R. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118751 · Cited by 579

Cardiovascular and Metabolic Effects of ANGPTL3 Antisense Oligonucleotides

Graham, M. J., Lee, R. G., Brandt, T. A., Tai, L.-J., Fu, W., Peralta, R., Yu, R., Hurh, E., Paz, E., McEvoy, B. W., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701329 · Cited by 573

Molecular Mechanisms of Cellular Cholesterol Efflux

Phillips, M. C. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.r114.583658 · Cited by 568

Extreme Lipoprotein(a) Levels and Risk of Myocardial Infarction in the General Population

Kamstrup, P. R., Benn, M., Tybjærg‐Hansen, A., & Nordestgaard, B. G. (2007) · Circulation · doi:10.1161/circulationaha.107.715698 · Cited by 566

Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia

Gaudet, D., Alexander, V. J., Baker, B. F., Brisson, D., Tremblay, K., Singleton, W., Geary, R. S., Hughes, S. G., Viney, N. J., Graham, M. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1400283 · Cited by 528 · cited 1×

NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis

Tsimikas, S., Fazio, S., Ferdinand, K. C., Ginsberg, H. N., Koschinsky, M. L., Marcovina, S. M., Moriarty, P. M., Rader, D. J., Remaley, A. T., Reyes‐Soffer, G., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.014 · Cited by 519

Population-based resequencing of ANGPTL4 uncovers variations that reduce triglycerides and increase HDL

Romeo, S., Pennacchio, L. A., Fu, Y., Boerwinkle, E., Tybjaerg-Hansen, A., Hobbs, H. H., & Cohen, J. C. (2007) · Nature Genetics · doi:10.1038/ng1984 · Cited by 511

Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis

Pinkosky, S. L., Newton, R. S., Day, E. A., Ford, R. J., Lhotak, S., Austin, R. C., Birch, C. M., Smith, B. K., Filippov, S., Groot, P. H. E., et al. (2016) · Nature Communications · doi:10.1038/ncomms13457 · Cited by 498

Inactivating Variants in ANGPTL4 and Risk of Coronary Artery Disease

Dewey, F. E., Gusarova, V., O’Dushlaine, C., Gottesman, O., Trejos, J., Hunt, C., Van Hout, C. V., Habegger, L., Buckler, D., Lai, K.-M. V., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1510926 · Cited by 497

Coding Variation in ANGPTL4, LPL, and SVEP1 and the Risk of Coronary Disease

Myocardial Infarction Genetics and CARDIoGRAM Exome Consortia Investigators (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1507652 · Cited by 493

Targeting APOC3 in the familial chylomicronemia syndrome

Gaudet, D., Brisson, D., Tremblay, K., Alexander, V. J., Singleton, W., Hughes, S. G., Geary, R. S., Baker, B. F., Graham, M. J., Crooke, R. M., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400284 · Cited by 491

VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial

Sacks, F. M., Alaupovic, P., Moye, L. A., Cole, T. G., Sussex, B., Stampfer, M. J., Pfeffer, M. A., & Braunwald, E. (2000) · Circulation · doi:10.1161/01.cir.102.16.1886 · Cited by 490

ANGPTL3 deficiency and protection against coronary artery disease

Stitziel, N. O., Khera, A. V., Wang, X., Bierhals, A. J., Vourakis, A. C., Sperry, A. E., Natarajan, P., Klarin, D., Emdin, C. A., Zekavat, S. M., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.02.030 · Cited by 467

Plasma lipoproteins: genetic influences and clinical implications

Hegele, R. A. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2481 · Cited by 462

Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study

Tsimikas, S., Viney, N. J., Hughes, S. G., Singleton, W., Graham, M. J., Baker, B. F., Burkey, J. L., Yang, Q., Marcovina, S. M., Geary, R. S., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(15)61252-1 · Cited by 460

Familial hypercholesterolaemia

Defesche, J. C., Gidding, S. S., Harada-Shiba, M., Hegele, R. A., Santos, R. D., & Wierzbicki, A. S. (2017) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2017.93 · Cited by 453

Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: A randomized, placebo-controlled study

Ballantyne, C. M., Banach, M., Mancini, G. B. J., Lepor, N. E., Hanselman, J. C., Zhao, X., & Leiter, L. A. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.06.002 · Cited by 422

Inactivating Mutations in NPC1L1 and Protection from Coronary Heart Disease

The Myocardial Infarction Genetics Consortium Investigators (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1405386 · Cited by 419

A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma

Bergmark, C., Dewan, A. K., Orsoni, A., Merki, E., Miller, E. R., Shin, M., Binder, C. J., Hörkkö, S., Krauss, R. M., Chapman, M. J., et al. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m800174-jlr200 · Cited by 410

Efficacy and long-term safety of alipogene tiparvovec (AAV1-LPLS447X) gene therapy for lipoprotein lipase deficiency: an open-label trial

Gaudet, D., Méthot, J., Déry, S., Brisson, D., Essiembre, C., Tremblay, G., Tremblay, K., de Wal, J., Twisk, J., van den Bulk, N., et al. (2013) · Gene Therapy · doi:10.1038/gt.2012.43 · Cited by 404

Association Between Low-Density Lipoprotein Cholesterol–Lowering Genetic Variants and Risk of Type 2 Diabetes: A Meta-analysis

Lotta, L. A., Sharp, S. J., Burgess, S., Perry, J. R. B., Stewart, I. D., Willems, S. M., Luan, J., Ardanaz, E., Arriola, L., Balkau, B., et al. (2016) · JAMA · doi:10.1001/jama.2016.14568 · Cited by 394

PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study

Schmidt, A. F., Swerdlow, D. I., Holmes, M. V., Patel, R. S., Fairhurst-Hunter, Z., Lyall, D. M., Hartwig, F. P., Horta, B. L., Hyppönen, E., Power, C., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30396-5 · Cited by 380

Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans

Graham, M. J., Lee, R. G., Bell, T. A., Fu, W., Mullick, A. E., Alexander, V. J., Singleton, W., Viney, N., Geary, R., Su, J., et al. (2013) · Circulation Research · doi:10.1161/circresaha.111.300367 · Cited by 377

Chylomicronaemia–current diagnosis and future therapies

Brahm, A. J., & Hegele, R. A. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.26 · Cited by 356

HDL-targeted therapies: progress, failures and future

Kingwell, B. A., Chapman, M. J., Kontush, A., & Miller, N. E. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4279 · Cited by 354

High-Density Lipoprotein Cholesterol and Cause-Specific Mortality in Individuals Without Previous Cardiovascular Conditions

Ko, D. T., Alter, D. A., Guo, H., Koh, M., Lau, G., Austin, P. C., Booth, G. L., Hogg, W. E., Jackevicius, C. A., Lee, D. S., et al. (2016) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.08.038 · Cited by 340

Human knockouts and phenotypic analysis in a cohort with a high rate of consanguinity

Saleheen, D., Natarajan, P., Armean, I. M., Zhao, W., Rasheed, A., Khetarpal, S. A., Won, H.-H., Karczewski, K. J., O’Donnell-Luria, A. H., Samocha, K. E., et al. (2017) · Nature · doi:10.1038/nature22034 · Cited by 340

ANGPTL3 inhibition in homozygous familial hypercholesterolemia

Gaudet, D., Gipe, D. A., Pordy, R., Ahmad, Z., Cuchel, M., Shah, P. K., Chyu, K.-Y., Sasiela, W. J., Chan, K.-C., Brisson, D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1705994 · Cited by 323

Relationship of Apolipoproteins A-1 and B, and Lipoprotein(a) to Cardiovascular Outcomes

Albers, J. J., Slee, A. E., O’Brien, K. D., Robinson, J. G., Kashyap, M. L., Kwiterovich, P. O., Xu, P., & Marcovina, S. M. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.06.051 · Cited by 317

Lipoprotein (a): truly a direct prothrombotic factor in cardiovascular disease?

Boffa, M. B., & Koschinsky, M. L. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r060582 · Cited by 309

The complex molecular genetics of familial hypercholesterolaemia

Berberich, A. J., & Hegele, R. A. (2018) · Nature Reviews Cardiology · doi:10.1038/s41569-018-0052-6 · Cited by 298

Angiopoietin-Like Protein3 Regulates Plasma HDL Cholesterol Through Suppression of Endothelial Lipase

Shimamura, M., Matsuda, M., Yasumo, H., Okazaki, M., Fujimoto, K., Kono, K., Shimizugawa, T., Ando, Y., Koishi, R., Kohama, T., et al. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000252827.51626.89 · Cited by 297

ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors

Gordts, P. L. S. M., Nock, R., Son, N.-H., Ramms, B., Lew, I., Gonzales, J. C., Thacker, B. E., Basu, D., Lee, R. G., Mullick, A. E., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci86610 · Cited by 274 · cited 2×

The Evolving Future of PCSK9 Inhibitors

Rosenson, R. S., Hegele, R. A., Fazio, S., & Cannon, C. P. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.04.054 · Cited by 264

A Phase 3 Trial of Sebelipase Alfa in Lysosomal Acid Lipase Deficiency

Burton, B. K., Balwani, M., Feillet, F., Barić, I., Burrow, T. A., Grande, C. C., Çöker, M., Consuelo‐Sánchez, A., Deegan, P. B., Rocco, M. D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501365 · Cited by 253

Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a)

Leibundgut, G., Scipione, C. A., Yin, H., Schneider, M., Boffa, M. B., Green, S., Yang, X., Dennis, E. A., Witztum, J. L., Koschinsky, M. L., et al. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m040733 · Cited by 246

Mipomersen, an Apolipoprotein B Synthesis Inhibitor, Reduces Atherogenic Lipoproteins in Patients With Severe Hypercholesterolemia at High Cardiovascular Risk

Thomas, G. S., Cromwell, W. C., Ali, S., Chin, W., Flaim, J. D., & Davidson, M. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.07.081 · Cited by 245

AMP-activated protein kinase and ATP-citrate lyase are two distinct molecular targets for ETC-1002, a novel small molecule regulator of lipid and carbohydrate metabolism

Pinkosky, S. L., Filippov, S. I., Srivastava, R. A. K., Hanselman, J. C., Bradshaw, C. D., Hurley, T. R., Cramer, C. T., Spahr, M. A., Brant, A. F., Houghton, J. L., et al. (2012) · Journal of Lipid Research · doi:10.1194/jlr.m030528 · Cited by 241

Apolipoprotein C-II: new findings related to genetics, biochemistry, and role in triglyceride metabolism

Wolska, A., Dunbar, R. L., Freeman, L. A., Ueda, M., Amar, M. J., Sviridov, D. O., & Remaley, A. T. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.10.025 · Cited by 231

Lipoprotein Apheresis for Lipoprotein(a)-Associated Cardiovascular Disease: Prospective 5 Years of Follow-Up and Apolipoprotein(a) Characterization

Roeseler, E., Julius, U., Heigl, F., Spitthoever, R., Heutling, D., Breitenberger, P., Leebmann, J., Lehmacher, W., Kamstrup, P. R., Nordestgaard, B. G., et al. (2016) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.116.307983 · Cited by 227

PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role

Raal, F. J., Giugliano, R. P., Sabatine, M. S., Koren, M. J., Blom, D. J., Seidah, N. G., Honarpour, N., Lira, A., Xue, A. X., Chiruvolu, P., et al. (2016) · Journal of Lipid Research · doi:10.1016/j.jlr.2026.101063 · Cited by 226

Long-term treatment with evolocumab added to conventional drug therapy, with or without apheresis, in patients with homozygous familial hypercholesterolaemia: an interim subset analysis of the open-label TAUSSIG study

Raal, F. J., Hovingh, G. K., Blom, D. J., Santos, R. D., Harada‐Shiba, M., Bruckert, É., Couture, P., Soran, H., Watts, G. F., Kurtz, C. E., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30044-x · Cited by 223

In Vivo Base Editing of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) as a Therapeutic Alternative to Genome Editing

Chadwick, A. C., Wang, X., & Musunuru, K. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.309881 · Cited by 223

Severe hypertriglyceridemia is primarily polygenic

Dron, J. S., Wang, J., Cao, H., McIntyre, A. D., Iacocca, M. A., Menard, J. R., Movsesyan, I., Malloy, M. J., Pullinger, C. R., Kane, J. P., et al. (2019) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2018.10.006 · Cited by 222

ANGPTL3 blockade with a human monoclonal antibody reduces plasma lipids in dyslipidemic mice and monkeys

Gusarova, V., Alexa, C. A., Wang, Y., Rafique, A., Kim, J. H., Buckler, D., Mintah, I. J., Shihanian, L. M., Cohen, J. C., Hobbs, H. H., et al. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m054890 · Cited by 210

Apolipoprotein CIII in Apolipoprotein B Lipoproteins Enhances the Adhesion of Human Monocytic Cells to Endothelial Cells

Kawakami, A., Aikawa, M., Libby, P., Alcaide, P., Luscinskas, F. W., & Sacks, F. M. (2006) · Circulation · doi:10.1161/circulationaha.105.591743 · Cited by 206

High density lipoproteins: Measurement techniques and potential biomarkers of cardiovascular risk

Hafiane, A., & Genest, J. J. (2015) · BBA Clinical · doi:10.1016/j.bbacli.2015.01.005 · Cited by 204

Association of rare and common variation in the lipoprotein lipase gene with coronary artery disease

Khera, A. V., Won, H.-H., Peloso, G. M., O’Dushlaine, C., Liu, D., Stitziel, N. O., Natarajan, P., Nomura, A., Emdin, C. A., Gupta, N., et al. (2017) · JAMA · doi:10.1001/jama.2017.0972 · Cited by 198

Levels and Changes of HDL Cholesterol and Apolipoprotein A-I in Relation to Risk of Cardiovascular Events Among Statin-Treated Patients: A Meta-Analysis

Boekholdt, S. M., Arsenault, B. J., Hovingh, G. K., Mora, S., Pedersen, T. R., LaRosa, J. C., Welch, K. M. A., Amarenco, P., DeMicco, D. A., Tonkin, A. M., et al. (2013) · Circulation · doi:10.1161/circulationaha.113.002670 · Cited by 196

Effect of Serial Infusions of CER-001, a Pre-β High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial

Nicholls, S. J., Andrews, J., Kastelein, J. J. P., Merkely, B. P., Nissen, S. E., Ray, K. K., Schwartz, G. G., Worthley, S. G., Keyserling, C., Dasseux, J., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.2121 · Cited by 191

Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion

Wang, Y., Gusarova, V., Banfi, S., Gromada, J., Cohen, J. C., & Hobbs, H. H. (2015) · Journal of Lipid Research · doi:10.1194/jlr.m054882 · Cited by 189

Variant ASGR1 Associated with a Reduced Risk of Coronary Artery Disease

Nioi, P., Sigurdsson, A., Thorleifsson, G., Helgason, H., Agustsdottir, A. B., Norddahl, G. L., Helgadottir, A., Magnusdottir, A., Jonasdottir, A., Gretarsdottir, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1508419 · Cited by 189

Apolipoprotein C-III: from pathophysiology to pharmacology

Norata, G. D., Tsimikas, S., Pirillo, A., & Catapano, A. L. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2015.07.001 · Cited by 182

Gene therapy for lipoprotein lipase deficiency

Gaudet, D., Méthot, J., & Kastelein, J. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e3283555a7e · Cited by 178

Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial

Nicholls, S. J., Puri, R., Ballantyne, C. M., Jukema, J. W., Kastelein, J. J. P., Köenig, W., Wright, R. S., Kallend, D. G., Wijngaard, P. L. J., Borgman, M., et al. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.2112 · Cited by 178

Very-low-density lipoprotein-associated apolipoproteins predict cardiovascular events and are lowered by inhibition of APOC-III

Pechlaner, R., Tsimikas, S., Yin, X., Willeit, P., Baig, F., Santer, P., Oberhollenzer, F., Egger, G., Witztum, J. L., Alexander, V. J., et al. (2017) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2016.11.065 · Cited by 171

High-Density Lipoprotein Cholesterol and Mortality

Hamer, M., O’Donovan, G., & Stamatakis, E. A. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.310587 · Cited by 171

Efficacy and Safety of ETC-1002, a Novel Investigational Low-Density Lipoprotein-Cholesterol–Lowering Therapy for the Treatment of Patients With Hypercholesterolemia and Type 2 Diabetes Mellitus

Gutierrez, M. J., Rosenberg, N. L., MacDougall, D. E., Hanselman, J. C., Margulies, J. R., Strange, P., Milad, M. A., McBride, S. J., & Newton, R. S. (2014) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.302677 · Cited by 170

LDL Containing Apolipoprotein CIII Is an Independent Risk Factor for Coronary Events in Diabetic Patients

Lee, S.-J., Campos, H., Moye, L. A., & Sacks, F. M. (2003) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.0000066131.01313.eb · Cited by 170

Antisense-mediated lowering of plasma apolipoprotein C-III by volanesorsen improves dyslipidemia and insulin sensitivity in type 2 diabetes

Digenio, A., Dunbar, R. L., Alexander, V. J., Hompesch, M., Morrow, L., Lee, R. G., Graham, M. J., Hughes, S. G., Yu, R., Singleton, W., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0126 · Cited by 170

Assessment of omega-3 carboxylic acids in statin-treated patients with high levels of triglycerides and low levels of high-density lipoprotein cholesterol: rationale and design of the STRENGTH trial

Nicholls, S. J., Lincoff, A. M., Bash, D., Ballantyne, C. M., Barter, P. J., Davidson, M. H., Kastelein, J. J. P., Koenig, W., McGuire, D. K., Mozaffarian, D., et al. (2018) · Clinical Cardiology · doi:10.1002/clc.23055 · Cited by 167

Effect of Alipogene Tiparvovec (AAV1-LPL S447X ) on Postprandial Chylomicron Metabolism in Lipoprotein Lipase-Deficient Patients

Carpentier, A. C., Frisch, F., Labbé, S. M., Gagnon, R., de Wal, J., Greentree, S., Petry, H., Twisk, J., Brisson, D., & Gaudet, D. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3002 · Cited by 165

Clinical and biochemical features of different molecular etiologies of familial chylomicronemia

Hegele, R. A., Berberich, A. J., Ban, M. R., Wang, J., Digenio, A., Alexander, V. J., D'Erasmo, L., Arca, M., Jones, A., Bruckert, E., et al. (2018) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2018.03.093 · Cited by 165

Effects of Pemafibrate, a Novel Selective PPARα Modulator, on Lipid and Glucose Metabolism in Patients With Type 2 Diabetes and Hypertriglyceridemia: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial

Araki, E., Yamashita, S., Arai, H., Yokote, K., Satoh, J., Inoguchi, T., Nakamura, J., Maegawa, H., Yoshioka, N., Tanizawa, Y., et al. (2018) · Diabetes Care · doi:10.2337/dc17-1589 · Cited by 164

Angptl3 Deficiency Is Associated With Increased Insulin Sensitivity, Lipoprotein Lipase Activity, and Decreased Serum Free Fatty Acids

Robciuc, M. R., Maranghi, M., Lahikainen, A., Rader, D., Bensadoun, A., Öörni, K., Metso, J., Minicocci, I., Ciociola, E., Ceci, F., et al. (2013) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.113.301397 · Cited by 163

Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance

Thompson, P. D., Rubino, J., Janik, M. J., MacDougall, D. E., McBride, S. J., Margulies, J. R., & Newton, R. S. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.03.003 · Cited by 158

Genetic Inhibition of CETP, Ischemic Vascular Disease and Mortality, and Possible Adverse Effects

Johannsen, T. H., Frikke-Schmidt, R., Schou, J., Nordestgaard, B. G., & Tybjærg-Hansen, A. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.07.045 · Cited by 156

Antisense Oligonucleotide Directed to Human Apolipoprotein B-100 Reduces Lipoprotein(a) Levels and Oxidized Phospholipids on Human Apolipoprotein B-100 Particles in Lipoprotein(a) Transgenic Mice

Merki, E., Graham, M. J., Mullick, A. E., Miller, E. R., Crooke, R. M., Pitas, R. E., Witztum, J. L., & Tsimikas, S. (2008) · Circulation · doi:10.1161/circulationaha.108.786822 · Cited by 156

Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension

Santos, R. D., Duell, P. B., East, C. A., Guyton, J. R., Moriarty, P. M., Chin, W., & Mittleman, R. S. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht549 · Cited by 149

HDL and atherosclerotic cardiovascular disease: genetic insights into complex biology

Rosenson, R. S., Brewer, H. B., Barter, P. J., Björkegren, J., Chapman, M. J., Gaudet, D., Kim, D. S., Niesor, E. J., Rye, K., Sacks, F. M., et al. (2017) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.115 · Cited by 149

Genetic inactivation of ANGPTL4 improves glucose homeostasis and is associated with reduced risk of diabetes

Gusarova, V., O’Dushlaine, C., Teslovich, T. M., Benotti, P. N., Mirshahi, T., Gottesman, O., Van Hout, C. V., Murray, M. F., Mahajan, A., Nielsen, J. B., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-04611-z · Cited by 145

Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance

Thompson, P. D., MacDougall, D. E., Newton, R. S., Margulies, J. R., Hanselman, J. C., Orloff, D. G., McKenney, J. M., & Ballantyne, C. M. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.12.025 · Cited by 142

Long-Term Efficacy and Safety of the Microsomal Triglyceride Transfer Protein Inhibitor Lomitapide in Patients With Homozygous Familial Hypercholesterolemia

Blom, D. J., Averna, M. R., Meagher, E. A., Theron, H. D. T., Sirtori, C. R., Hegele, R. A., Shah, P. K., Gaudet, D., Stefanutti, C., Vigna, G. B., et al. (2017) · Circulation · doi:10.1161/circulationaha.117.028208 · Cited by 141

Is raising HDL a futile strategy for atheroprotection?

JOY, T. R., & Hegele, R. A. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2489 · Cited by 139

The risk of cardiovascular events with increased apolipoprotein CIII: a systematic review and meta-analysis

Wyler von Ballmoos, M. C., Haring, B., & Sacks, F. M. (2015) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2015.05.002 · Cited by 134

Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans

Graham, M. J., Viney, N., Crooke, R. M., & Tsimikas, S. (2016) · Journal of Lipid Research · doi:10.1194/jlr.r052258 · Cited by 133

Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia

Duell, P. B., Santos, R. D., Kirwan, B., Witztum, J. L., Tsimikas, S., & Kastelein, J. J. P. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.04.013 · Cited by 132

The Effects of 2′- O -Methoxyethyl Containing Antisense Oligonucleotides on Platelets in Human Clinical Trials

Crooke, S. T., Baker, B. F., Witztum, J. L., Kwoh, T. J., Pham, N. C., Salgado, N., McEvoy, B. W., Cheng, W., Hughes, S. G., Bhanot, S., et al. (2017) · Nucleic Acid Therapeutics · doi:10.1089/nat.2016.0650 · Cited by 129 · cited 1×

Antisense Oligonucleotide Lowers Plasma Levels of Apolipoprotein (a) and Lipoprotein (a) in Transgenic Mice

Merki, E., Graham, M., Taleb, A., Leibundgut, G., Yang, X., Miller, E. R., Fu, W., Mullick, A. E., Lee, R., Willeit, P., et al. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.10.052 · Cited by 124

Hepatic Proprotein Convertases Modulate HDL Metabolism

Jin, W., Wang, X., Millar, J. S., Quertermous, T., Rothblat, G. H., Glick, J. M., & Rader, D. J. (2007) · Cell Metabolism · doi:10.1016/j.cmet.2007.07.009 · Cited by 120

Effect of ETC-1002 on Serum Low-Density Lipoprotein Cholesterol in Hypercholesterolemic Patients Receiving Statin Therapy

Ballantyne, C. M., McKenney, J. M., MacDougall, D. E., Margulies, J. R., Robinson, P. L., Hanselman, J. C., & Lalwani, N. D. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.03.043 · Cited by 119

Apolipoproteins C–III and E in apoB- and non-apoB-containing lipoproteins in two populations at contrasting risk for myocardial infarction: the ECTIM study. Etude Cas Temoins sur 'Infarctus du Myocarde

Luc, G., Fievet, C., Arveiler, D., Evans, A. E., Bard, J. M., Cambien, F., Fruchart, J. C., & Ducimetiere, P. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37594-5 · Cited by 114

Genetics of Triglycerides and the Risk of Atherosclerosis

Dron, J. S., & Hegele, R. A. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0667-9 · Cited by 114

Effect of the DGAT1 inhibitor pradigastat on triglyceride and apoB48 levels in patients with familial chylomicronemia syndrome

Meyers, C. D., Tremblay, K., Amer, A., Chen, J., Jiang, L., & Gaudet, D. (2015) · Lipids in Health and Disease · doi:10.1186/s12944-015-0006-5 · Cited by 110

Missense Mutation in APOC3 within the C-terminal Lipid Binding Domain of Human ApoC-III Results in Impaired Assembly and Secretion of Triacylglycerol-rich Very Low Density Lipoproteins

Qin, W., Sundaram, M., Wang, Y., Zhou, H., Zhong, S., Chang, C.-C., Manhas, S., Yao, E. F., Parks, R. J., McFie, P. J., et al. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.203679 · Cited by 107

The discovery and development of HMG-CoA reductase inhibitors

Endo, A. (2004) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2004.08.026 · Cited by 106

Targeted next-generation sequencing in monogenic dyslipidemias

Hegele, R. A., Ban, M. R., Cao, H., McIntyre, A. D., Robinson, J. F., & Wang, J. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000163 · Cited by 106

Lipoprotein(a): more interesting than ever after 50 years

Dubé, J. B., Boffa, M. B., Hegele, R. A., & Koschinsky, M. L. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32835111d8 · Cited by 105

Apheresis as novel treatment for refractory angina with raised lipoprotein(a): a randomized controlled cross-over trial

Khan, T. Z., Hsu, L., Arai, A. E., Rhodes, S., Pottle, A., Wage, R., BANYA, W. A. S., Gatehouse, P. D., Giri, S., Collins, P. D., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehx178 · Cited by 105

Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling and hormone secretion in the gut with intolerable side effects: a randomized clinical trial

Denison, H., Nilsson, C., Löfgren, L., Himmelmann, A., Mårtensson, G., Knutsson, M., AL‐Shurbaji, A., Tornqvist, H., & Eriksson, J. W. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12221 · Cited by 104

Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results

Yang, X., Lee, S.-R., Choi, Y.-S., Alexander, V. J., Digenio, A., Yang, Q., Miller, Y. I., Witztum, J. L., & Tsimikas, S. (2016) · Journal of Lipid Research · doi:10.1194/jlr.m066399 · Cited by 103

Apolipoprotein C-III and hepatic triglyceride-rich lipoprotein production

Yao, Z., & Wang, Y. (2012) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328352dc70 · Cited by 100

Apolipoprotein CIII-Induced THP-1 Cell Adhesion to Endothelial Cells Involves Pertussis Toxin-Sensitive G Protein- and Protein Kinase Cα-Mediated Nuclear Factor-κB Activation

Kawakami, A., Aikawa, M., Nitta, N., Yoshida, M., Libby, P., & Sacks, F. M. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000249620.68705.0d · Cited by 99

Clinical characteristics and plasma lipids in subjects with familial combined hypolipidemia: a pooled analysis

Minicocci, I., Santini, S., Cantisani, V., Stitziel, N., Kathiresan, S., Arroyo, J. A., Martí, G., Pisciotta, L., Noto, D., Cefalù, A. B., et al. (2013) · Journal of Lipid Research · doi:10.1194/jlr.p039875 · Cited by 97

Familial lecithin:cholesterol acyltransferase deficiency: First-in-human treatment with enzyme replacement

Shamburek, R. D., Bakker‐Arkema, R., Auerbach, B. J., et al. (2015) · Journal of clinical lipidology · doi:10.1016/j.jacl.2015.12.007 · Cited by 97

Prevention of Diet-Induced Metabolic Dysregulation, Inflammation, and Atherosclerosis in Ldlr −/− Mice by Treatment With the ATP-Citrate Lyase Inhibitor Bempedoic Acid

Samsoondar, J. P., Burke, A. C., Sutherland, B. G., Telford, D. E., Sawyez, C. G., Edwards, J. Y., Pinkosky, S. L., Newton, R. S., & Huff, M. W. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.308963 · Cited by 96

How to use Mendelian randomization to anticipate the results of randomized trials

Ference, B. A. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx462 · Cited by 96

Assessment of the clinical effects of cholesteryl ester transfer protein inhibition with evacetrapib in patients at high-risk for vascular outcomes: Rationale and design of the ACCELERATE trial

Nicholls, S. J., Lincoff, A. M., Barter, P. J., Brewer, H. B., Fox, K. A. A., Gibson, C. M., Grainger, C., Menon, V., Montalescot, G., Rader, D. J., et al. (2015) · American Heart Journal · doi:10.1016/j.ahj.2015.09.007 · Cited by 94

Lipoprotein (a) in calcific aortic valve disease: from genomics to novel drug target for aortic stenosis

Thanassoulis, G. (2015) · Journal of Lipid Research · doi:10.1194/jlr.r051870 · Cited by 94

ATP-citrate lyase: genetics, molecular biology and therapeutic target for dyslipidemia

Burke, A. C., & Huff, M. W. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000390 · Cited by 91

Triglyceride-rich lipoproteins and remnants: targets for therapy?

Dallinga-Thie, G. M., Kroon, J., Borén, J., & Chapman, M. J. (2016) · Current Cardiology Reports · doi:10.1007/s11886-016-0745-6 · Cited by 90

Effect of Bile Acid Sequestrants on the Risk of Cardiovascular Events: A Mendelian Randomization Analysis

Ross, S., D’Mello, M., Anand, S. S., Eikelboom, J., CARDIoGRAMplusC4D Consortium*, Stewart, A. F. R., Samani, N. J., Roberts, R., & Paré, G. (2015) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.114.000952 · Cited by 90

Genetic linkage between lipoprotein(a) phenotype and a DNA polymorphism in the plasminogen gene

Drayna, D. T., Hegele, R. A., Hass, P. E., et al. (1988) · Genomics · doi:10.1016/0888-7543(88)90084-5 · Cited by 87

Safety and Tolerability of ACP-501, a Recombinant Human Lecithin:Cholesterol Acyltransferase, in a Phase 1 Single-Dose Escalation Study

Shamburek, R. D., Bakker-Arkema, R. G., Shamburek, A. M., Freeman, L. A., Amar, M. J., Auerbach, B. J., Krause, B. R., Homan, R., Adelman, S. J., Collins, H. L., et al. (2015) · Circulation Research · doi:10.1161/circresaha.115.306223 · Cited by 81

Plasma Apolipoprotein C-III Levels, Triglycerides, and Coronary Artery Calcification in Type 2 Diabetics

Qamar, A., Khetarpal, S. A., Khera, A. V., Qasim, A., Rader, D. J., & Reilly, M. P. (2015) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.305415 · Cited by 79

Genetics of Lipid and Lipoprotein Disorders and Traits

Dron, J. S., & Hegele, R. A. (2016) · Current Genetic Medicine Reports · doi:10.1007/s40142-016-0097-y · Cited by 78

Monogenic pediatric dyslipidemias: Classification, genetics and clinical spectrum

Rahalkar, A. R., & Hegele, R. A. (2007) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2007.10.007 · Cited by 77

Lomitapide for the treatment of hypercholesterolemia

Berberich, A. J., & Hegele, R. A. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1340941 · Cited by 77

Model-based development of gemcabene, a new lipid-altering agent

Mandema, J. W., Hermann, D. J., Wang, W., et al. (2005) · The AAPS Journal · doi:10.1208/aapsj070352 · Cited by 74

Efficacy and safety of mipomersen in treatment of dyslipidemia: A meta-analysis of randomized controlled trials

Panta, R., Dahal, K. B., & Kunwar, S. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.12.006 · Cited by 71

Apolipoprotein C-III: Going Back to the Future for a Lipid Drug Target

Huff, M. W., & Hegele, R. A. (2013) · Circulation Research · doi:10.1161/circresaha.113.301464 · Cited by 70

Increased Plasma Apolipoprotein C-III Concentration Independently Predicts Cardiovascular Mortality: The Hoorn Study

Scheffer, P. G., Teerlink, T., Dekker, J. M., Bos, G., Nijpels, G., Diamant, M., Kostense, P. J., Stehouwer, C. D. A., & Heine, R. J. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.103234 · Cited by 68

Dysfunctional high-density lipoproteins have distinct composition, diminished anti-inflammatory potential and discriminate acute coronary syndrome from stable coronary artery disease patients

Carnuta, M. G., Stancu, C. S., Toma, L., Sanda, G. M., Niculescu, L. S., Deleanu, M., Popescu, A. C., Popescu, M. R., Vlad, A., Dimulescu, D. R., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-07821-5 · Cited by 66

Nonstatin Low-Density Lipoprotein–Lowering Therapy and Cardiovascular Risk Reduction—Statement From ATVB Council

Hegele, R. A., Gidding, S. S., Ginsberg, H. N., McPherson, R., Raal, F. J., Rader, D. J., Robinson, J. G., & Welty, F. K. (2015) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.115.306442 · Cited by 63

Relationship between “LDL-C”, estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide

Viney, N. J., Yeang, C., Yang, X., Xia, S., Witztum, J. L., & Tsimikas, S. (2018) · Journal of clinical lipidology · doi:10.1016/j.jacl.2018.02.014 · Cited by 63

Apolipoprotein genetic variation in the assessment of atherosclerosis susceptibility

Hegele, R. A., Breslow, J. L., & Cloninger, C. R. (1987) · Genetic Epidemiology · doi:10.1002/gepi.1370040302 · Cited by 60

Lipoprotein(a) Genetic Variants Associated With Coronary and Peripheral Vascular Disease but Not With Stroke Risk in the Heart Protection Study

Hopewell, J. C., Clarke, R., Parish, S., Armitage, J., Lathrop, M. G., Hager, J., & Collins, R. (2011) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.110.958371 · Cited by 60

Functional analysis of the missense APOC3 mutation Ala23Thr associated with human hypotriglyceridemia

Sundaram, M., Zhong, S., Khalil, M. B., Zhou, H., Jiang, Z. G., Zhao, Y., Iqbal, J., Hussain, M. M., Figeys, D., Wang, Y., et al. (2010) · Journal of Lipid Research · doi:10.1194/jlr.m005108 · Cited by 58

Creation of Apolipoprotein C-II (ApoC-II) Mutant Mice and Correction of Their Hypertriglyceridemia with an ApoC-II Mimetic Peptide

Sakurai, T., Sakurai, A., Vaisman, B. L., Amar, M. J., Liu, C., Gordon, S. M., Drake, S. K., Pryor, M., Sampson, M. L., Yang, L., et al. (2015) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.115.229740 · Cited by 58

Effects of mipomersen, an apolipoprotein B100 antisense, on lipoprotein (a) metabolism in healthy subjects

Nandakumar, R., Matveyenko, A., Thomas, T. A., Pavlyha, M., Ngai, C. I., Holleran, S., Ramakrishnan, R., Ginsberg, H. N., Karmally, W., Marcovina, S. M., et al. (2018) · Journal of Lipid Research · doi:10.1194/jlr.p082834 · Cited by 58

Effects of angiopoietin-like protein 3 deficiency on postprandial lipid and lipoprotein metabolism

Minicocci, I., Tikka, A., Poggiogalle, E., Metso, J., Montali, A., Ceci, F., Labbadia, G., Fontana, M., Di Costanzo, A., Maranghi, M., et al. (2016) · Journal of Lipid Research · doi:10.1194/jlr.p066183 · Cited by 56

Non-Clinical Study Examining AAV8.TBG.hLDLR Vector-Associated Toxicity in Chow-Fed Wild-Type and LDLR +/− Rhesus Macaques

Greig, J. A., Limberis, M. P., Bell, P., Chen, S.-J., Calcedo, R., Rader, D. J., & Wilson, J. M. (2017) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2017.014 · Cited by 56

Predicting inhibitory and activatory drug targets by chemically and genetically perturbed transcriptome signatures

Sawada, R., Iwata, M., Tabei, Y., Yamato, H., & Yamanishi, Y. (2018) · Scientific Reports · doi:10.1038/s41598-017-18315-9 · Cited by 54

Efficacy and safety of gemcabene as add-on to stable statin therapy in hypercholesterolemic patients

Stein, E., Bays, H. E., Koren, M. J., Bakker-Arkema, R. G., & Bisgaier, C. L. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.08.002 · Cited by 52

HDL re-examined

Hovingh, G. K., Rader, D. J., & Hegele, R. A. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000161 · Cited by 51

Atorvastatin Decreases Apolipoprotein C-III in Apolipoprotein B-Containing Lipoprotein and HDL in Type 2 Diabetes

Dallinga‐Thie, G. M., Berk-Planken, I. I. L., Bootsma, A. H., Jansen, H., & on behalf of the Diabetes Atorvastatin Lipid Intervention (DALI) Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.6.1358 · Cited by 51

Recent Developments in Gene Therapy for Homozygous Familial Hypercholesterolemia

Ajufo, E., & Cuchel, M. (2016) · Current Atherosclerosis Reports · doi:10.1007/s11883-016-0579-0 · Cited by 51

Mipomersen and lomitapide: Two new drugs for the treatment of homozygous familial hypercholesterolemia

Gouni‐Berthold, I., & Berthold, H. K. (2015) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2015.02.005 · Cited by 49

The effect of volanesorsen treatment on the burden associated with familial chylomicronemia syndrome: the results of the ReFOCUS study

Arca, M., Hsieh, A., Soran, H., Rosenblit, P., O’Dea, L., & Stevenson, M. (2018) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2018.1487290 · Cited by 49

Pharmacokinetics, pharmacodynamics, safety, and tolerability of pradigastat, a novel diacylglycerol acyltransferase 1 inhibitor in overweight or obese, but otherwise healthy human subjects

Meyers, C. D., Amer, A., Majumdar, T., & Chen, J. (2015) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.509 · Cited by 47

Pediatric experience with mipomersen as adjunctive therapy for homozygous familial hypercholesterolemia

Raal, F. J., Braamskamp, M. J. A. M., Selvey, S., Sensinger, C., & Kastelein, J. J. P. (2016) · Journal of clinical lipidology · doi:10.1016/j.jacl.2016.02.018 · Cited by 47

Modulating cholesterol efflux capacity to improve cardiovascular disease

Brownell, N. K., & Rohatgi, A. K. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000317 · Cited by 46

Bempedoic Acid Lowers Low-Density Lipoprotein Cholesterol and Attenuates Atherosclerosis in Low-Density Lipoprotein Receptor–Deficient ( LDLR +/− and LDLR −/− ) Yucatan Miniature Pigs

Burke, A. C., Telford, D. E., Sutherland, B. G., Edwards, J. Y., Sawyez, C. G., Barrett, P. H. R., Newton, R. S., Pickering, J. G., & Huff, M. W. (2018) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.310676 · Cited by 46

Effectiveness and tolerability of a new lipid-altering agent, gemcabene, in patients with low levels of high-density lipoprotein cholesterol

Bays, H. E., McKenney, J. M., Dujovne, C. A., et al. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00721-5 · Cited by 45

LDL-cholesterol reduction in patients with hypercholesterolemia by modulation of adenosine triphosphate-citrate lyase and adenosine monophosphate-activated protein kinase

Filippov, S. I., Pinkosky, S. L., & Newton, R. S. (2014) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000091 · Cited by 44

Novel therapeutics in hypertriglyceridemia

Gryn, S. E., & Hegele, R. A. (2015) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000231 · Cited by 44

Developing Medicines That Mimic the Natural Successes of the Human Genome

Kathiresan, S. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.02.049 · Cited by 43

Nonclinical Pharmacology/Toxicology Study of AAV8.TBG.mLDLR and AAV8.TBG.hLDLR in a Mouse Model of Homozygous Familial Hypercholesterolemia

Greig, J. A., Limberis, M. P., Bell, P. L., Chen, S., Calcedo, R., Rader, D. J., & Wilson, J. M. (2017) · Human Gene Therapy Clinical Development · doi:10.1089/humc.2017.007 · Cited by 43

Nucleic Acid–Based Therapies for Atherosclerosis

Mäkinen, P. I., Ruotsalainen, A., & Ylä‐Herttuala, S. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-0826-2 · Cited by 43

Association of cholesteryl ester transfer protein (CETP) gene polymorphism, high density lipoprotein cholesterol and risk of coronary artery disease: a meta-analysis using a Mendelian randomization approach

Wu, Z., Lou, Y., Qiu, X., Liu, Y., Lu, L., Chen, Q., & Jin, W. (2014) · BMC Medical Genetics · doi:10.1186/s12881-014-0118-1 · Cited by 40 · cited 1×

Large-Scale Analysis of Determinants, Stability, and Heritability of High-Density Lipoprotein Cholesterol Efflux Capacity

Koekemoer, A. L., Codd, V., Masca, N. G. D., Nelson, C. P., Musameh, M. D., Kaess, B. M., Hengstenberg, C., Rader, D. J., & Samani, N. J. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.309201 · Cited by 40

The apolipoprotein C-III (Gln38Lys) variant associated with human hypertriglyceridemia is a gain-of-function mutation

Sundaram, M., Curtis, K. R., Alipour, M. A., LeBlond, N. D., Margison, K. D., Yaworski, R., Parks, R. J., McIntyre, A. D., Hegele, R. A., Fullerton, M. D., et al. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m077313 · Cited by 40

Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis (The MICA-Study)

Waldmann, E., Vogt, A., Crispin, A., Altenhofer, J., Riks, I., & Parhofer, K. G. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.02.019 · Cited by 39

Lipoprotein Apheresis

Moriarty, P. M., & Hemphill, L. (2016) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2015.09.003 · Cited by 39

Changes in LDL size phenotypes associate with changes in apolipoprotein C-III glycoforms after dietary interventions

Mendoza, S., Trenchevska, O., King, S. M., Nelson, R., Nedelkov, D., Krauss, R., & Yassine, H. N. (2016) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2016.12.009 · Cited by 37

Bempedoic Acid (ETC-1002): ATP Citrate Lyase Inhibitor

Zagelbaum, N. K., Yandrapalli, S., Nabors, C. C., & Frishman, W. H. (2018) · Cardiology in Review · doi:10.1097/crd.0000000000000218 · Cited by 37

Cholesteryl Ester Transfer Protein Inhibition Is Not Yet Dead—Pro

Barter, P. J., & Rye, K. (2016) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.115.306879 · Cited by 36

HDL—is it too big to fail?

Ng, D. S., Wong, N. C. W., & Hegele, R. A. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.238 · Cited by 34

Apolipoprotein A-I Infusion Therapies for Coronary Disease: Two Outs in the Ninth Inning and Swinging for the Fences

Rader, D. J. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.2168 · Cited by 32

Multidimensional regulation of lipoprotein lipase: impact on biochemical and cardiovascular phenotypes

Hegele, R. A. (2016) · Journal of Lipid Research · doi:10.1194/jlr.c070946 · Cited by 31

Leveraging human genetics to guide drug target discovery

Stitziel, N. O., & Kathiresan, S. (2016) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2016.08.008 · Cited by 31

Novel lipid modifying drugs to lower LDL cholesterol

Cupido, A. J., Reeskamp, L. F., & Kastelein, J. J. P. (2017) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000428 · Cited by 30

History of lipidology and lipoprotein apheresis

Julius, U. (2017) · Atherosclerosis Supplements · doi:10.1016/j.atherosclerosissup.2017.05.034 · Cited by 30

Angiopoietin-like protein 4: a therapeutic target for triglycerides and coronary disease?

Olshan, D. S., & Rader, D. J. (2018) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2018.01.012 · Cited by 30

Gemcabene downregulates inflammatory, lipid-altering and cell-signaling genes in the STAM™ model of NASH

Oniciu, D. C., Hashiguchi, T., Shibazaki, Y., & Bisgaier, C. L. (2018) · PLoS ONE · doi:10.1371/journal.pone.0194568 · Cited by 27

Effect of Vupanorsen on Non–High-Density Lipoprotein Cholesterol Levels in Statin-Treated Patients With Elevated Cholesterol: TRANSLATE-TIMI 70

Bergmark, B. A., Marston, N. A., Bramson, C. R., Curto, M., Ramos, V., Jevne, A., Kuder, J. F., Park, J.-G., Murphy, S. A., Verma, S., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.059266 · Cited by 216

Rare dyslipidaemias, from phenotype to genotype to management: a European Atherosclerosis Society task force consensus statement

Hegele, R. A., Borén, J., Ginsberg, H. N., Arca, M., Averna, M., Binder, C. J., Calabresi, L., Chapman, M. J., Cuchel, M., von Eckardstein, A., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30264-5 · Cited by 204

The dawn of a new era of targeted lipid-lowering therapies

Tokgözoğlu, L., & Libby, P. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehab841 · Cited by 171

Genetic testing in dyslipidemia: A scientific statement from the National Lipid Association

Brown, E. E., Sturm, A. C., Cuchel, M., Braun, L. T., Duell, P. B., Underberg, J. A., Jacobson, T. A., & Hegele, R. A. (2020) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2020.04.011 · Cited by 148

Remnant cholesterol, coronary atheroma progression and clinical events in statin-treated patients with coronary artery disease

Elshazly, M. B., Mani, P., Nissen, S., Brennan, D. M., Clark, D., Martin, S., Jones, S. R., Quispe, R., Donnellan, E., Nicholls, S. J., et al. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487319887578 · Cited by 103

ФОРМИРОВAНИЕ ГОТОВНОСТИ БУДУЩИХ ПЕДAГОГОВ К ОРГAНИЗAЦИИ РAБОТЫ ПО РAЗВИТИЮ ВAЛЕОЛОГИЧЕСКОЙ КУЛЬТУРЫ ШКОЛЬНИКОВ

БАЗАРБАЕВА, Ә. А., Майгельдиева, Ш. М., & ЖҮНДІБАЕВА, Т. Н. (2023) · Pedagogy and Psychology · doi:10.51889/2077-6861.2023.1.30.016

Коммуникaтивно- прaгмaтический aнaлиз дипломaтических бумaг (нa основе вербaльных нот)

Кaмирдиновa, Н., & Кaлиевa, Ш. С. (2018) · DOAJ (DOAJ: Directory of Open Access Journals)

DETERMINING QUALITY REQUIREMENTS AT THE UNIVERSITIES TO IMPROVE THE QUALITY OF EDUCATION

Mustafa, N. H., Kelesbayev, D., & Alibekova, Z. D. (2018) · The Journal of Economic Research & Business Administration · doi:10.26577/be-2018-2-2141

Susquehanna Chorale Spring Concert "Roots and Wings"

Hawkins, D. (2017)

A GEOMETRIC MEAN IN THE FURUTA INEQUALITY

Fujii, M., & Nakamoto, R. (2002) · Scientiae mathematicae Japonicae · Cited by 15